VACCINEX INC (VCNX)
US9186403013 - Common Stock
VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023
Vaccinex just reported results for the fourth quarter of 2023.
VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaccinex (NASDAQ:VCNX) just reported results for the fourth quarter of 2023.Vac...
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024....
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and...
Vaccinex, Inc. Announces Reverse Stock Split
Vaccinex prices $3.7M PIPE financing (NASDAQ:VCNX)
Vaccinex announced a $3.7M private placement transaction, featuring a major new investor and participation from existing investors, selling shares and...
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
Vaccinex files to sell 712,484 shares for holders (NASDAQ:VCNX)
Vaccinex (VCNX) files prospectus for resale of 712,484 shares of common stock by selling stockholders. Not an offer to sell securities.
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 ...
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with head and neck cancer and melanoma
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of...
Why Is Near Intelligence (NIR) Stock Down 20% Today?
Near Intelligence stock is falling hard on Friday as an updated filing from the company reveals several problems facing NIR shares.
Why Is Omniq (OMQS) Stock Down 43% Today?
Omniq shares are taking a beating on Friday after the company announced the details of a $3 million public offering for OMQS stock.
Why Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?
RVL Pharmaceuticals stock is a hot topic on Friday as investors seek answers as to why RVLP stock is rally alongside heavy trading.
Why Is Vaccinex (VCNX) Stock Up 26% Today?
Vaccinex stock is climbing higher on Friday as investors react to company leaders recently acquiring more shares of VCNX stock.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting off Friday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!